Technical Analysis with a Quantitative Edge

SIGN UP  |  LOGIN

HOW IT WORKS    TRADE SIGNALS    SCREENER    MY PORTFOLIO    HELP

Merrimack Pharmaceuticals, Inc. (MACK)
Equity - Health Care - Major Pharmaceuticals

 

As of 2017-08-17

Add to My Portfolio
Close1.24Open1.26
Prev Close1.27Daily Chg-0.03 (-2.36%)
High1.27Volume717,360
Low1.2452-Week High/Low6.68 / 1.16
Dividend Yield0%Curr P/E0.39
Curr Year EPS Est3.36Fwd P/E0.37
P/B1.58Short Ratio5.24
P/S1.17PEG Ratio0.07
Latest QuantForecast
As Of
Customize QuantForecast   View Commentary & Pattern   Save To My Forecasts     Share

 
 
 

SUPPORT
Lower Boll Band: 1.22
RESISTANCE
9EMA: 1.27 20SMA: 1.29 50SMA: 1.31
COMMENTARY
Strong downtrend across all timeframes . However, Momentum is improving with On Balance Volume trending higher. Forecast points to lower price with conviction
TECHNICAL PATTERN

TYPEDESCRIPTION (?)CRITERIA (?)
Oversold Condition Slow Stochastics K Line near historical low at 9.78, occurred 8.22% of the time Slow Stochastics K Line = 9.78 +- 0.89
Long-Term Down Trend 200-Day Simple Moving Average is Trending Lower 200SMA Trend < 0
FORECAST STATISTICS
TIMEFRAME 2-DAY 5-DAY 10-DAY 20-DAY
Average -0.22% -2.42% -4.45% -8.37%
Best +8.86% +25.68% +19.77% +23.38%
Worst -10.70% -16.18% -22.93% -42.39%
% Positive 47% 33% 33% 27%
Outlook NEUTRAL BEARISH BEARISH BEARISH
HISTORICAL MATCHES (?)
MATCH DATE 2-DAY 5-DAY 10-DAY 20-DAY
2017-08-17 0% 0% 0% 0%
2016-12-16 +3.47% -16.18% -22.93% -42.39%
2016-08-17 +1.22% -0.81% -5.91% -4.48%
2016-08-12 -1.54% -4.05% -8.49% -8.88%
2016-04-28 -0.14% -9.05% -14.81% -10.29%
2016-04-27 -1.80% -11.37% -9.29% -6.93%
2016-01-12 -3.99% +1.23% -3.07% -16.90%
2015-12-15 +1.89% -4.03% +1.89% -21.28%
2014-02-07 +4.80% +1.67% +4.18% +23.38%
2014-02-03 -0.83% +1.88% +6.46% +15.21%
2014-01-31 -4.38% -8.76% -7.24% -0.76%
# Matches 15 Next
TRADE SIGNALS ?
POSITIONENTRY DATEENTRY PRICETARGET PRICE (?)STOP PRICE (?)CURRENT PNL %
Premium Members Only

Upgrade Now & Subscribe to Daily Trade Signals

CLOSED TRADES
POSITIONENTRY DATEENTRY PRICEEXIT DATE EXIT PRICEREALIZED PNL %
Short 2016-03-21 8.30 2016-04-28 7.29 +12.17%
Long 2014-04-29 4.49 2014-05-08 6.38 +42.09%
Related Stocks
SYMBOL NAME Close VOLUME CHG WTD MTD YTD QUANTFORECAST(?)
2-DAY 5-DAY 10-DAY 20-DAY
JNJ Johnson & Johnson 133.07 3,937,406 -1.09 (-0.81%) -0.04 (-0.03%) +0.35 (+0.26%) +18.61 (+16.26%)
PFE Pfizer, Inc. 32.96 10,654,858 -0.40 (-1.20%) -0.29 (-0.87%) -0.22 (-0.66%) +1.11 (+3.50%)
MRK Merck & Company, Inc. 61.81 8,747,324 -0.89 (-1.42%) -0.59 (-0.95%) -2.12 (-3.32%) +3.37 (+5.76%)
SNY Sanofi 48.12 525,563 -0.28 (-0.58%) +0.52 (+1.09%) +0.74 (+1.56%) +7.68 (+18.99%)
ABBV AbbVie Inc. 69.88 4,504,956 -0.55 (-0.78%) -0.77 (-1.09%) -0.05 (-0.07%) +8.52 (+13.89%)
>>> See More Related Stocks
LATEST BUZZ
@poostinky
Posted 2017-08-18T14:08:13Z
$MACK F U!
@DosGatos
Posted 2017-08-18T13:43:07Z
$MACK Beast Mode
@JaHolland
Posted 2017-08-18T13:15:42Z
$MACK Down in premarket. Green today?
@scistats
Posted 2017-08-18T12:34:27Z
$MACK New U.S. MM-141 patent http://www.freepatentsonline.com/y2017/0233491.html
@OldGlory
Posted 2017-08-18T12:17:32Z
$MACK hurry up
@stockflare_alerts
Posted 2017-08-18T09:25:11Z
$MACK: The forecast EPS for Merrimack Pharmaceuticals Inc has increased to $3.36 from $3.12 in the last week. (https://stockflare.com/stock/MACK.O)
@mehrotrasam
Posted 2017-08-17T22:43:04Z
$SGYP going like $MACK .. shareholders. We're given $1 dividend and rest of 1B was given away
@TheBee
Posted 2017-08-17T21:08:14Z
$MACK good news that with a stock with no volume doesn't lose much on bad market days
@TheBee
Posted 2017-08-17T21:06:48Z
$MACK 2 weeks until September...when's that WF news coming, again?
@jathman
Posted 2017-08-17T20:11:29Z
$MACK Crocker unleashing value every day
@MisterBroGuy
Posted 2017-08-17T18:43:03Z
$MACK just sitting here with my 2.30 avg like a bag holding douche
@kgainey5
Posted 2017-08-17T14:57:49Z
$MACK boring
@scistats
Posted 2017-08-17T13:03:21Z
$MACK KITE: 17 patients with a variety of metastatic solid tumors. Responses were observed in 4 patients. http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=1037572
@Jumping_Jack
Posted 2017-08-17T11:52:32Z
$MACK will buy next week.
@DosGatos
Posted 2017-08-17T01:20:00Z
$MACK That nice lil 1.25ish to 1.35ish channel appears to have dried up so you know what time it is?
@scistats
Posted 2017-08-16T22:16:33Z
$MACK Onivyde "protein corona" (PC) boosts its uptake into pancreas ductal adenocarcinoma cells. Likely same for MM-302 and MM-310?
@tradetraderson
Posted 2017-08-16T21:32:54Z
$MACK asked a few days ago, since R/S is happening anyone anticipate the typical pump before split?
@DosGatos
Posted 2017-08-16T20:21:54Z
$MACK +2 cents?! Ummmmm YEAH!!!!!
@MisterBroGuy
Posted 2017-08-16T17:51:43Z
$MACK any of you guys looked into $AKER at all? Seems like good news is coming
@TheBee
Posted 2017-08-16T14:00:38Z
$MACK back in at 1.25.
MACK LATEST NEWS
Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls
Posted Thu, 10 Aug 2017 16:39:49 Z
Merrimack Pharmaceuticals Inc MACK reported a loss of 22 cents per share in the second quarter of 2017 wider than the Zacks Consensus Estimate of a loss of 14 cents The company had reported a loss of 41 cents in the year ago quarter Merrimack completed the sale of Onivyde and a... >>> Read More
Merrimack's (MACK) Reports Wider-than-Expected Q2 Loss
Posted Wed, 09 Aug 2017 13:39:18 Z
Cambridge MA based Merrimack Pharmaceuticals Inc MACK is a biopharmaceutical company focused on the discovery development and commercialization of innovative therapies in combination with companion diagnostics for the treatment of cancer Merrimack completed the sale of its only... >>> Read More
What's in the Cards for Merrimack (MACK) in Q2 Earnings?
Posted Fri, 28 Jul 2017 16:58:43 Z
Merrimack Pharmaceuticals Inc MACK is expected to report second quarter 2017 results around Aug 3 Last quarter Merrimack missed bottom line expectations by 214 29 Merrimack s share price has decreased 67 4 year to date against the industry s gain of 10 Let s see how things... >>> Read More
These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop?
Posted Wed, 21 Jun 2017 21:23:17 Z
It looks like an especially cruel summer lies ahead for XBiotech Inc NASDAQ XBIT Merrimack Pharmaceuticals Inc NASDAQ MACK and NewLink Genetics Corp NASDAQ NLNK The market has already dragged these biotechs out behind the tool shed and spent a few months... >>> Read More
Merrimack Completes Enrollment in Phase II Study for MM-141
Posted Tue, 20 Jun 2017 16:23:05 Z
Merrimack Pharmaceuticals Inc MACK announced completion of enrollment in the ongoing phase II study CARRIE evaluating its pipeline candidate MM 141 istiratumab in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer In... >>> Read More

WINGCHARTS.COM    HOW IT WORKS    TRADE SIGNALS    SCREENER    MY PORTFOLIO    HELP

 



Follow Us on StockTwits
Partners / Affiliates

Copyright © 2017 WingCapital Co., Ltd. All Rights Reserved.

Disclaimer: Past results are not necessarily indicative of future performance. This website is for educational purposes only. No content published in this website, services and products constitutes a recommendation that any particular investment, security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Practical use of the content, forecasts, charts and services provided in this website are at your own risk and WingCapital Co., Ltd., WingCharts.com, its partners, representatives and employees assume no responsibility or liability for any use of the website. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Trade signals shown are hypothetical and do not represent actual trades. Actual results may differ. Views, forecasts and commentaries expressed in this website are WingCapital Co., Ltd.'s own opinions, and are not guarantees of future performance, and are subject to change over time.

WingCharts.com and WingCapital Co., Ltd. are not registered investment advisor or a broker dealer and do not give individualized market advice. The information on this website is for illustration purposes only and should not be considered as a solicitation of an offer on the purchase or sale of any securities. Trading in the securities markets involves substantial risk and should not be undertaken without due diligence and serious independent study. WingCapital Co., Ltd. recommends consulting a licensed professional broker regarding your personal investments. Without limitation, WingCapital Co., Ltd. shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscribers inability to use or any delay in accessing the WingCharts.com website or any other source of material provided by WingCharts.com and WingCapital Co., Ltd.; (3) any absence or error of material on WingCharts.com website or presentation; (4) WingCapital Co., Ltd. failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material.

ALL INFORMATION AND MATERIALS ARE PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.